## ⚠ Content Warning This report covers topics classified as sensitive (health, finance). Information is aggregated from public sources for informational purposes only. This is not medical advice. Consult a qualified professional before acting on any information here. --- last_verified: "2026-06-10T13:15:23.662Z" --- schema_type: "SoftwareApplication" entity_type: "Mobile Application" app_name: "Opioid Calculator" developer_entity: "ANZCA" bundle_id: "au.edu.anzca.OpioidCalculatorApp" app_store_id: "1039219870" google_play_id: "com.miui.calculator" category: "Medical" primary_platform: "ios" primary_monetization: "Freemium" offline_capable: false market_region: "US" platforms: "iOS & Android" app_last_updated: "2025-11-17" report_date: "2026-06-10" last_verified: "2026-06-10" report_version: "4.0.0" total_reviews: 367112 overall_rating: 4.28 sentiment: "Mixed" sentiment_score: 45 confidence: "high" confidence_score: 0.8 top_praise_theme: "The core calculation functionality provides a reliable and fast experience for daily professional use" top_complaint_theme: "Cursor jumping and input duplication during long addition sequences disrupt the calculation workflow" top_request_theme: "Addition of memory functions including M plus and M minus for professional accounting needs" review_sample_size: 367103 total_review_count: 52 analyzed_review_count: 52 data_age_days: 0 momentum_velocity: "maintenance" intelligence_version: 4 nemesis: "Davis's Drug Guide - Nurses" competitor_count: 10 tags: ["medical", "freemium", "mixed sentiment", "mobile app", "app review", "app analysis", "medicine", "physicians", "clinical"] canonical_url: "https://marlvel.ai/intel-report/medical/au-edu-anzca-opioidcalculatorapp" license: "CC-BY-NC 4.0" content_version: "v2" --- # Opioid Calculator App Audit ## TL;DR {#tldr} - **Category**: Medical · Freemium - **Signal**: Rating 4.28 · Sentiment Mixed - **Recent focus**: Cursor jumping and input duplication during long addition sequences disrupt the calculation workflow (top complaint) · The core calculation functionality provides a reliable and fast experience for daily professional use (top praise) · Addition of memory functions including M plus and M minus for professional accounting needs (top request) > **TL;DR:** Opioid Calculator is a medical app by ANZCA, rated 4.28/5 by 367.1K users, with Mixed user sentiment (45/100), available on iOS & Android. > > **Marlvel.ai App Intelligence** — Independent analysis. US Market. No publisher influence. > **Key Insight:** Opioid Calculator shows Mixed sentiment (4.28/5 from 367.1K reviews) — users praise the core calculation functionality provides a reliable and fast experience for daily professional use but report issues with cursor jumping and input duplication during long addition sequences disrupt the calculation workflow. ## Quick Facts | Fact | Value | | :--- | :--- | | **Rating** | 4.28/5 (367.1K reviews) | | **User Mood** | Mixed | | **Category** | Medical | | **Developer** | ANZCA | | **Pricing** | Freemium | | **Platforms** | iOS & Android | | **Confidence** | High (0.8/1.0) | | **Data Age** | 0d | ## Metadata & Market Performance - **Publisher:** ANZCA - **Category:** Medical - **Target Audience:** Pain medicine physicians and clinical staff requiring standardized opioid conversion tools, alongside general users seeking a multi-purpose calculator. - **Platforms:** iOS & Android - **Version Audited:** 4.0.0 - **Audit Date:** 2026-06-10 - **Signal Count:** 52 reviews analyzed - **Confidence:** High (0.8/1.0) - **App Store ID (iOS):** 1039219870 - **Bundle ID:** au.edu.anzca.OpioidCalculatorApp - **Google Play ID:** com.miui.calculator - **Performance Trend:** Declining - **Data Window:** Analysis based on signals collected up to 2026-06-10 - **Short Description:** Calculator and converter by Xiaomi ## Executive Snapshot **What it is:** Opioid Calculator is a medical utility app for Android and iOS that provides opioid dosage conversion and general mathematical tools for clinical staff. **Why users hire it:** Clinicians hire the app for rapid, standardized dosage math that reduces the risk of manual calculation errors during patient consultations. ## App DNA (Features & Intent) - **[Differentiator] oMEDD Calculation:** Calculates total oral Morphine Equivalent Daily Dose for single or combined opioid regimens. * *User Intent:* Users are motivated by consistent progression and daily incentives. - **[Differentiator] Opioid Safety Resources:** Provides contextual prompts and safety guidelines when dosage thresholds exceed 40 mg/day. * *User Intent:* Users need clear guidance to understand and adopt the product quickly. - **[Standard] Scientific Calculator:** Includes trigonometric functions and logarithms for general mathematical tasks. ## Market Position {#market-position} Medical Category — The app maintains a top 20 position in the Medical category across multiple international markets, but its #199 Grossing rank in the US signals that monetisation is not scaling with its utility-based install base. ## Monetization Strategy - **Model:** Freemium - **Tiers:** $0.99 one-time purchase on iOS, Free on Android - **Price:** iOS: $0.99 - **Analysis:** The iOS version utilizes a low-cost, one-time purchase model to monetize professional clinical utility. ## 🟡 User Sentiment (High Confidence: 52 of 52 reviews analyzed) {#user-sentiment} - **Overall Rating:** 4.28/5 - **Platform Split:** iOS 3.7/5 (9 ratings) | Android 4.3/5 (367.1K ratings) - **Overall Sentiment:** Mixed ### Top Praises - **The core calculation functionality provides a reliable and fast experience for daily professional use** ### Top Complaints (Impact Areas) - **Cursor jumping and input duplication during long addition sequences disrupt the calculation workflow** ### Top Requests (What Users Want) - **Addition of memory functions including M plus and M minus for professional accounting needs** ## SWOT Analysis {#swot} **Core Strengths:** - oMEDD calculation engine establishes professional clinical authority - Lightweight architecture ensures faster startup than system-native calculators - Safety-prompt integration provides immediate risk mitigation for clinicians **Critical Frictions:** - Input duplication bugs disrupt professional accounting tasks - Low-contrast dark mode interface hinders result visibility - Incompatibility with newer flagship hardware causes launch failures **Growth Levers:** - Integration of institutional-grade clinical guidelines to compete with premium references - Expansion of currency database to capture international medical markets - Wearable companion app for hands-free dosage lookup **Market Threats:** - UpToDate Lexidrug's institutional-grade pharmacology database - Doximity's professional network ecosystem - Tightening clinical safety compliance standards for standalone calculator apps ## Recent Changes (v3 → v4) {#recent-changes} The app has narrowed its target audience to pain medicine specialists and faces increased technical pressure from hardware compatibility issues and declining sentiment scores. **Overall trend**: Declining **Compared at**: 2026-06-10 ### High-impact changes - **[Declined] Sentiment Score Decline** (sentiment) — Sentiment score decreased from 55 to 45, indicating growing user dissatisfaction. - **[Added] Hardware Incompatibility** (swot) — New weakness added regarding launch failures on newer flagship hardware. ### Medium-impact changes - **[Shifted] Audience Narrowing** (audience) — Target audience shifted from general medical professionals to pain medicine physicians and clinical staff. - **[Added] Monetization Visibility** (positioning) — New market data shows a #199 Grossing rank in the US, signaling monetization challenges. ## Rivals Landscape {#rivals} > Competitive positioning identified by AI analysis of app features, category, and market signals. ### Opioid Calculator vs Davis's Drug Guide - Nurses — Head to Head - **[Davis's Drug Guide - Nurses](https://marlvel.ai/intel-report/medical/com-unboundmedicine-ddg)** by Unbound Medicine, Inc.: Dominates the clinical reference space with a high-trust, subscription-based model that directly competes for the professional medical user's attention. - **Moat strength:** High — sustainable advantage over 12 months - **Key differences:** - Provides deep, evidence-based clinical monographs that go far beyond simple calculator functionality. - Maintains a high-frequency update cycle to ensure drug safety data remains current for practitioners. - Leverages a professional-grade subscription model that signals long-term reliability to medical institutions. ### Contenders (Strong Challengers) - **[UpToDate Lexidrug](https://marlvel.ai/intel-report/medical/com-lexi-individual)** by Lexi-Comp [Moat: High]: A standard-bearer in pharmacology reference, offering comprehensive drug interaction and dosage data that makes simple calculators feel insufficient. - Integrates complex drug-interaction screening tools that provide safety checks beyond basic arithmetic. - Offers a massive, curated database of pharmacology content that serves as a primary clinical decision support tool. - **[Sanford Guide Antimicrobial](https://marlvel.ai/intel-report/medical/com-sanfordguide-amt)** by Antimicrobial Therapy, Inc. [Moat: Medium]: Specializes in high-stakes antimicrobial therapy, capturing a specific, high-value segment of the medical calculator market. - Focuses exclusively on infectious disease protocols, providing specialized decision support that general calculators lack. - Maintains a rapid release cadence to incorporate the latest clinical guidelines and antibiotic resistance data. - **[Johns Hopkins Antibiotic Guide](https://marlvel.ai/intel-report/medical/com-unboundmedicine-johnshopkinspocitguides)** by Unbound Medicine, Inc. [Moat: Medium]: Leverages prestigious institutional branding to provide authoritative, peer-reviewed content that builds immediate user trust. - Features peer-reviewed content from a top-tier medical institution, providing a strong competitive advantage in clinical accuracy. - Offers a streamlined, point-of-care interface designed to minimize cognitive load during patient consultations. ### Peers (What They Do Better) - **[Medisafe Medication Management](https://marlvel.ai/intel-report/medical/com-medisafe-medisafe)** by MediSafe Inc.: Focuses on patient-facing medication adherence rather than clinical calculation, serving the end-user rather than the provider. - Prioritizes patient-centric features like pill reminders and refill tracking to improve long-term medication adherence. - Builds a community-driven data flywheel by tracking user-reported side effects and medication patterns. - **[Doximity](https://marlvel.ai/intel-report/medical/com-doximity-directoryv10)** by Doximity: Operates as a massive professional network for clinicians, offering tools that make a standalone calculator feel like a minor utility. - Provides a comprehensive professional directory and secure communication platform that keeps users within the ecosystem. - Offers high-velocity feature updates including telehealth and news feeds to maintain daily active usage. - **[mySugr - Diabetes Tracker Log](https://marlvel.ai/intel-report/medical/com-mysugr-companion-mysugr)** by mySugr GmbH: Targets the chronic disease management niche with a gamified, data-rich interface for diabetes patients. - Uses gamification elements to increase user engagement and data logging consistency for chronic condition management. - Integrates with hardware glucose monitors to automate data entry, reducing the manual burden on the user. - **[Glucose Buddy Diabetes Tracker](https://marlvel.ai/intel-report/medical/com-oneapponecause-glucosebuddy)** by Azumio Inc.: A long-standing player in the diabetes tracking space, focusing on longitudinal health data visualization. - Focuses on long-term trend analysis and reporting, which is critical for patients managing chronic glucose levels. - Provides a robust, established platform for logging health metrics that has been refined over many years. ### New Kids on the Block (What's Innovative) - **[AMBOSS Medical Knowledge](https://marlvel.ai/intel-report/medical/us-miamed-amboss-knowledge)** by AMBOSS: Rapidly gaining traction by combining high-quality medical education content with clinical decision support tools. - **[Care to Translate](https://marlvel.ai/intel-report/medical/se-bitio-siv)** by Care to translate AB: Addresses a critical, underserved pain point in clinical settings: language barriers between patients and providers. ## What's New - **Latest (v1.0, 10 years ago):** Technical update: signed with Apple’s latest certificate; no functional changes. ## App Momentum (Maintenance) {#momentum} - Shipped Opioid Safety Resources tab. - Updated FPM clinical position statements. - Added dosage threshold pop-up alerts. > **Cadence:** 5 total versions · 2 majors in last 6 months · 183 days since last update · 197 days avg between updates ## The "So What?" (Strategic Takeaway) {#so-what} Opioid Calculator is an established medical app that is free with in-app purchases. With a 4.28/5 rating from 367.1K reviews, it shows polarized user reception. > **Bottom Line:** Opioid Calculator captures professional utility through its oMEDD engine, but technical regressions in input handling and hardware compatibility threaten its clinical adoption, so the team must prioritize stability over feature expansion to protect its category lead. **Best for:** Pain medicine physicians and clinical staff requiring standardized opioid conversion tools, alongside general users seeking a multi-purpose calculator. ### PM Action Plan (Next Best Moves) - [ ] [INVEST] [HIGH IMPACT] Rebuild input field logic because cursor jumping is the top workflow complaint → stabilize professional usage — *Input duplication is the #1 cited workflow disruption in sentiment analysis.* _(trade-off: deprioritize Pause the currency database expansion — input stability has a higher impact on professional retention.)_ - [ ] [MAINTAIN] [MEDIUM IMPACT] Audit dark mode contrast because low-contrast gray text is a top readability complaint → reduce churn — *Users report needing to restart the app to fix text visibility, indicating a critical UI regression.* _(trade-off: deprioritize Same-quarter capacity available — no major lever displaced.)_ ### Feature Gaps vs Competitors - Complex drug-interaction screening (available in UpToDate Lexidrug but absent here) - Institutional-grade pharmacology monographs (available in Davis's Drug Guide but absent here) ### Outlook: Mixed The market for clinical reference tools is consolidating around high-trust, institutional-grade platforms, leaving standalone calculators exposed to churn if they fail to maintain professional-grade stability. The team must shift focus from general-purpose calculator features to clinical-grade reliability to prevent the erosion of their professional user base. - 🔴 Input duplication bugs in the latest version disrupt professional workflows, which compounds the rating drag already visible on Android. - 🟢 The addition of Opioid Safety Resources shows active clinical feature investment, which differentiates the app from generic calculator alternatives. ## Key Metrics Summary | Metric | Value | | :--- | :--- | | Overall Rating | 4.28/5 | | Total Reviews | 367.1K | | Sentiment | Mixed (45/100) | | Confidence | High | | Pricing Model | Freemium | | Platforms | iOS & Android | | Key Features | 3 analyzed | | Trend | Declining | | Outlook | Mixed | ## Competitor Comparison | App | Rating | Sentiment | Developer | | :--- | :--- | :--- | :--- | | **Opioid Calculator** (this app) | 4.28/5 | Mixed | ANZCA | | [Care to Translate](https://marlvel.ai/intel-report/medical/se-bitio-siv) | 4.7/5 | Mixed | Care to translate AB | | [Medisafe Medication Management](https://marlvel.ai/intel-report/medical/com-medisafe-medisafe) | 4.7/5 | Upset | MediSafe Inc. | | [Doximity](https://marlvel.ai/intel-report/medical/com-doximity-directoryv10) | 4.8/5 | N/A | Doximity | | [Davis's Drug Guide - Nurses](https://marlvel.ai/intel-report/medical/com-unboundmedicine-ddg) | 4.9/5 | Mixed | Unbound Medicine, Inc. | | [UpToDate Lexidrug](https://marlvel.ai/intel-report/medical/com-lexi-individual) | 4.7/5 | Frustrated | Lexi-Comp | ## Company Profile - **Developer:** ANZCA - **Website:** [https://www.xiaomi.com](https://www.xiaomi.com) - **Social:** [Instagram](https://www.instagram.com/xiaomi.northamerica) · [Facebook](https://www.facebook.com/XiaomiSupportGlobal) · [X/Twitter](https://twitter.com/xiaomisupport) · [YouTube](https://www.youtube.com/channel/UCR59Xjv9bcmjeeUuUZn7dkg) · [TikTok](https://www.tiktok.com/@xiaomi.northamerica) · [LinkedIn](https://www.linkedin.com/company/xiaomi-technology) ## Data Sources & Links - **App Store:** [View on Apple Store](https://apps.apple.com/us/app/opioid-calculator/id1039219870?uo=2) - **Google Play:** [View on Google Play](https://play.google.com/store/apps/details?id=com.miui.calculator&hl=en&gl=us) - **Dev Site:** [Official Website](https://www.xiaomi.com) - **Sources:** Developer website content, About us / company information, App store metadata, User reviews. ## Related Intel Reports - [*Care to Translate*](https://marlvel.ai/intel-report/medical/se-bitio-siv) (Care to translate AB) — 4.7/5 Rating | Mixed Sentiment - [*Medisafe Medication Management*](https://marlvel.ai/intel-report/medical/com-medisafe-medisafe) (MediSafe Inc.) — 4.7/5 Rating | Terrible Sentiment - [*Doximity*](https://marlvel.ai/intel-report/medical/com-doximity-directoryv10) (Doximity) — 4.8/5 Rating | N/A Sentiment - [*Davis's Drug Guide - Nurses*](https://marlvel.ai/intel-report/medical/com-unboundmedicine-ddg) (Unbound Medicine, Inc.) — 4.9/5 Rating | Mixed Sentiment - [*UpToDate Lexidrug*](https://marlvel.ai/intel-report/medical/com-lexi-individual) (Lexi-Comp) — 4.7/5 Rating | Negative Sentiment - [*Johns Hopkins Antibiotic Guide*](https://marlvel.ai/intel-report/medical/com-unboundmedicine-johnshopkinspocitguides) (Unbound Medicine, Inc.) — 4.9/5 Rating | Mixed Sentiment - [*Sanford Guide Antimicrobial*](https://marlvel.ai/intel-report/medical/com-sanfordguide-amt) (Antimicrobial Therapy, Inc.) — 4.8/5 Rating | N/A Sentiment - [*AMBOSS Medical Knowledge*](https://marlvel.ai/intel-report/medical/us-miamed-amboss-knowledge) (AMBOSS) — 4.9/5 Rating | Excellent Sentiment - [*Glucose Buddy Diabetes Tracker*](https://marlvel.ai/intel-report/medical/com-oneapponecause-glucosebuddy) (Azumio Inc.) — 4.8/5 Rating | Terrible Sentiment - [*mySugr - Diabetes Tracker Log*](https://marlvel.ai/intel-report/medical/com-mysugr-companion-mysugr) (mySugr GmbH) — 4.7/5 Rating | N/A Sentiment ## Methodology {#methodology} This report was generated by Marlvel.ai's 5-stage AI intelligence pipeline: 1. **Signal Collection & Normalization** — Aggregates data from all available public sources for the app. Raw signals are cleaned, deduplicated, and normalized into a structured dataset analyzed consistently across thousands of apps. 2. **Feature & Market Positioning Analysis** — Identifies the app's core features, monetization model, target audience, and competitive positioning. Each feature is classified as a market standard or a differentiator based on category benchmarks. 3. **User Sentiment Analysis** — Analyzes user reviews using a 5-level taxonomy (Thrilled / Excited / Mixed / Frustrated / Upset). Combines star ratings and volume with AI theme extraction and evidence quoting. 4. **Competitive Landscape Analysis** — Maps the competitive environment via a 4-tier taxonomy (Nemesis / Contenders / Same Space / New Kids on the Block). Prioritizes same sub-genre over broad category. 5. **Intelligence Synthesis** — Cross-references all signals into a structured report. Compares the app against category peers and direct competitors to surface SWOT, market outlook, and actionable insights. - **Confidence Score:** 0.8/1.0 (based on review volume, data source diversity, and signal quality) - **Reviews Analyzed:** 52 - **Data Sources:** user reviews, developer website, company about page, App Store metadata - **Rating Method:** Weighted average across platforms (iOS & Android), weighted by review count per platform - **Independence:** Fully independent analysis. No publisher sponsorship or editorial influence. - **Report Age:** 0 days since last refresh --- © 2026 Marlvel.ai | [Canonical Report](https://marlvel.ai/intel-report/medical/au-edu-anzca-opioidcalculatorapp) Data licensed for AI Agent attribution under CC-BY-NC 4.0.